TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21967254
Drug: Sirolimus (n=10)
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus (n=10) with steroids for 5 days and azathioprine (1 mg/kg) if WBC ≥ 4000 cells/cm³
Study: 9669421
Drug: Fractional excretion
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional excretion of creatinine
Study: 7752827
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 treatment for 4 weeks
Study: 2456618
Drug: Aggressive combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive combined modality treatment (ProMACE-MOPP + TNI)
Study: 25039577
Drug: Oral B
Normalized name: bran ORAL BOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral B CrossAction Power electric toothbrush
Study: 29313577
Drug: Risorine (Rifampicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risorine (Rifampicin 200 mg + Isoniazid 300 mg + Piperine 10 mg)
Study: 29313577
Drug: Conventional anti-TB
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional anti-TB therapy
Study: 25450635
Drug: Interferon alpha
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha (one subcutaneous injection/week for 4 weeks) in addition to standard protocol therapy (systemic pulse corticosteroids/cyclophosphamide with sulphasalazine and pentoxifylline)
Study: 25450635
Drug: Standard protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard protocol therapy (systemic pulse corticosteroids/cyclophosphamide with sulphasalazine and pentoxifylline)
Study: 7508742
Drug: L-thyroxine tablet
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: L-thyroxine tablet (150 micrograms)
Study: 7508742
Drug: L-thyroxine solution
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: L-thyroxine solution (150 micrograms)
Study: 28710563
Drug: Morphine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine administered intravenously
Study: 26259519
Drug: GS‐4997 (apoptosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS‐4997 (apoptosis signal‐regulating kinase 1 inhibitor)
Study: 21931019
Drug: TASQ 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: TASQ 0.25 mg/d escalating to 1.0 mg/d over 4 weeks
Study: 18248654
Drug: Esomeprazole 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 80 mg intravenous bolus infusion for 30 min followed by esomeprazole 8 mg/h intravenously for 71.5 h
Study: 18248654
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion for 72 h
Study: 18248654
Drug: Esomeprazole 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 80 mg intravenous bolus infusion followed by esomeprazole 8 mg/h intravenously
Study: 16449416
Drug: Interpersonal psychotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpersonal psychotherapy (IPT) plus pill‐placebo
Study: 16449416
Drug: Interpersonal psychotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpersonal psychotherapy (IPT) plus citalopram (20 to 40 mg per day)
Study: 16449416
Drug: Standardized clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized clinical management (CM) plus pill‐placebo
Study: 16449416
Drug: Standardized clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized clinical management (CM) plus citalopram (20 to 40 mg per day)
Study: 8739093
Drug: Dipyrone 3
Normalized name: dipyrone 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone 3 g/day
Study: 8739093
Drug: Dipyrone 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone 1.5 g/day
Study: 8739093
Drug: Paracetamol 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 1.5 g/day
Study: 7008184
Drug: 0.44 g
Normalized name: MENTHOL 0.44 g in 100 g / ZINC OXIDE 21 g in 100 g TOPICAL OINTMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.44 g acetylsalicylic acid (ASA)
Study: 7008184
Drug: 3.96 g
Normalized name: Avobenzone 2.088 g in 60 mL / HOMOSALATE 2.838 g in 60 mL / OCTISALATE 3.041 g in 60 mL / OCTOCRYLENE 1.733 g in 60 mL / OXYBENZONE 3.96 g in 60 mL TOPICAL CREAM [hope in a jar broad spectrum spf 25 sunscreen and moisturizer for all skin types]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.96 g acetylsalicylic acid (ASA)
Study: 30550301
Drug: CC (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC (control condition)
Study: 8251778
Drug: 5,6‐benzo‐alpha‐pyrone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5,6‐benzo‐alpha‐pyrone (200 mg tablets, two daily)
Study: 15958399
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two tablets daily)
Study: 2870876
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg loprazolam
Study: 31757794
Drug: Pioglitazone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone treatment for 12 weeks
Study: 31757794
Drug: Troglitazone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone treatment of cultured human adipocytes
Study: 29733520
Drug: Mango consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mango consumption (300 g for 4 weeks)
Study: 24161369
Drug: Liquid barium
Normalized name: barium
DrugBank: Barium (DB12481)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid barium thickened with a starch‐based agent (STARCH)
Study: 24161369
Drug: Liquid barium
Normalized name: barium
DrugBank: Barium (DB12481)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid barium thickened with a gum‐based agent (GUM)
Study: 18190615
Drug: Low-residue diet,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-residue diet, placebo fibre supplement, and loperamide
Study: 18190615
Drug: Fibre supplement,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibre supplement, neutral diet, and loperamide
Study: 15864137
Drug: Topical calcipotriol
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical calcipotriol treatment
Study: 12645717
Drug: Combined system
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined system (heparin-coated, centrifugal pump, closed circuit)
Study: 1804598
Drug: Ceftazidime 2
Normalized name: ceftazidime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 2 g twice a day i.v.
Study: 1804598
Drug: Ceftriaxone 2
Normalized name: ceftriaxone 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 2 g once daily i.v.
Study: 30057058
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Swedish massage and preferred music
Study: 26650825
Drug: Wait-list control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wait-list control group (received the program before the second chemotherapy cycle)
Study: 23146636
Drug: Moderate-to-severe pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-to-severe pain during injection
Study: 20491987
Drug: One-visit root
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-visit root canal treatment (n = 43)
Study: 20491987
Drug: Two-visit root
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-visit root canal treatment (n = 46)
Study: 19253522
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (80% of patients)
Study: 19253522
Drug: Monotherapy (20%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (20% of patients)
Study: 16012079
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of racemic lansoprazole
Study: 12945829
Drug: HMBCr (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMBCr (3 g/d HMB, 3 g/d Cr)
Study: 11012004
Drug: Sterile moisturizer
Normalized name: MOISTURIZER
DrugBank: Homosalate (DB11064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sterile moisturizer and sterile cleanser used in combination, applied once or twice daily for 28 days
Study: 8711553
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (0.4 g/kg/day for 5 days)
Study: 8711553
Drug: Placebo (similar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (similar volume daily for 5 days)
Study: 2005562
Drug: Ultrasound anterior
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound anterior capsule cleaning
Study: 22011265
Drug: Clindamycin 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin 40 mg/kg/24 h
Study: 22011265
Drug: First-generation cephalosporin
Normalized name: First-generation cephalosporins
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-generation cephalosporin 150 mg/kg/24 h
Study: 17509246
Drug: Biological markers
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological markers
Study: 16089138
Drug: Fuzheng quxie
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fuzheng quxie granule (FQG) + conventional western medicine (WM)
Study: 16089138
Drug: Conventional western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional western medicine (WM) alone
Study: 7843696
Drug: 28 weeks
Normalized name: migalastat
DrugBank: Migalastat (DB05018)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 28 weeks of natural IFN‐alpha treatment
Study: 7843696
Drug: 52 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 52 weeks of natural IFN‐alpha treatment
Study: 2146903
Drug: 20 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml/kg compound sodium lactate solution
Study: 2146903
Drug: 20 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml/kg compound sodium lactate solution + 1 g/kg dextrose
Study: 83088
Drug: 2% erythromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% erythromycin base in hydroalcoholic solution + 0.05% tretinoin solution
Study: 83088
Drug: 2% erythromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% erythromycin base in hydroalcoholic solution
Study: 29874199
Drug: LactoWise® (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: LactoWise® (4.5 billion live cells of bacillus coagulans and galactomannans, 300 mg)
Study: 29874199
Drug: Placebo (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (600 mg of calcium citrate yielding 126 mg of elemental calcium)
Study: 23500237
Drug: Ranolazine (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranolazine (target dose 1000 mg bid)
Study: 17461854
Drug: TMC114/r (600/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC114/r (600/100 mg bid)
Study: 17461854
Drug: TPV/r (500/200
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPV/r (500/200 mg bid)
Study: 12089852
Drug: Analgesic, hormonal,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic, hormonal, and surgical treatment
Study: 9642607
Drug: gemeprost 1
Normalized name: Gemeprost 1 mg vaginal pessary
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemeprost 1 mg 3 hourly for 5 doses
Study: 9642607
Drug: misoprostol 200
Normalized name: MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: misoprostol 200 mcg 6 hourly for 4 doses
Study: 7661175
Drug: Nabumetone, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabumetone, 1 g, b.i.d.
Study: 7661175
Drug: Naproxen, 500
Normalized name: Naproxen, 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen, 500 mg, b.i.d.
Study: 905127
Drug: Digoxin 20
Normalized name: digoxin 200 MCG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin 20 microgram/kg/day (loading dose of 20 microgram/kg followed by maintenance dose of 7 microgram/kg every 8 hours)
Study: 905127
Drug: Digoxin levels
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin levels exceeding 5 ng/ml
Study: 28712113
Drug: Receiving tuberculosis
Normalized name: Mycobacterium tuberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receiving tuberculosis treatment
Study: 26158605
Drug: Testosterone solution
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone solution 2% (60 mg applied to the axillae for 16 weeks)
Study: 22067312
Drug: Adjusted dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted dose (AD) of mycophenolate mofetil (MMF) using therapeutic drug monitoring (TDM)
Study: 22067312
Drug: Fixed-dose (FD)
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose (FD) regimen of mycophenolate mofetil (MMF)
Study: 19421770
Drug: FloSeal (5,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: FloSeal (5,000 U/5 mL)
Study: 19421770
Drug: Tabotamp (oxidized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tabotamp (oxidized regenerated cellulose patch, 2.5 x 5 cm)
Study: 15283801
Drug: Itraconazole (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (5 mg/kg/day, continuous regimen, either as capsule or oral suspension)
Study: 1958942
Drug: Three treatment
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three treatment regimes (behavioural approach to diet and weight gain coupled with individual and family psychotherapy)
Study: 1958942
Drug: Three treatment
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three treatment regimes
Study: 7053265
Drug: CTP (cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTP (cyclophosphamide 400 mg/m2/day orally X 5, teniposide 100 mg/m2 iv X 1, prednisolone 60 mg/m2/day orally X 5)
Study: 7053265
Drug: COP (vincristine
Approvals — FDA: no, EMA: no, PMDA: no
Description: COP (vincristine 1.4 mg/m2 iv X 1; maximum, 2 mg, with the same cyclophosphamide and prednisolone doses)
Study: 25342246
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (normothermic)
Study: 25072757
Drug: Simplified Severe
Normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simplified Severe Sepsis Protocol (up to 4 L of IV fluids within 6 hours, guided by jugular venous pressure assessment, and dopamine and/or blood transfusion in selected patients)
Study: 18047458
Drug: 30 minutes
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 minutes daily stretch of the wrist and finger flexors five days a week for four weeks
Study: 10420149
Drug: Bicalutamide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicalutamide (50 mg once daily) plus LHRHa (goserelin acetate 3.6 mg or leuprolide acetate 7.5 mg)
Study: 10420149
Drug: Flutamide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide (250 mg three times daily) plus LHRHa (goserelin acetate 3.6 mg or leuprolide acetate 7.5 mg)
Study: 7593526
Drug: Mifepristone (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (600 mg) plus sulprostone (250 micrograms)
Study: 19218542
Drug: d‐MPH‐ER 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐MPH‐ER 20 to 40 mg/d
Study: 16052676
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human IFN beta‐1a in combination with ribavirin (Group 2)
Study: 12444323
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) regimen 1 starting with 3 IR tablets (n = 15)
Study: 12444323
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) regimen 2 starting with 10 IR tablets (n = 16)
Study: 12444323
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) regimen 3 starting with 30 IR tablets (n = 16)
Study: 9635520
Drug: Controlled-release (CR)
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled-release (CR) morphine tablets administered every 12 hours
Study: 9635520
Drug: Immediate-release (IR)
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release (IR) morphine
Study: 4185887
Drug: Radioactive iodine
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radioactive iodine (131)I therapy
Study: 30203440
Drug: Bupivacaine 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 50 mg with adrenaline 100 μg (BA-group, n = 14)
Study: 29446060
Drug: Midazolam group
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam group (20 ml of bupivacaine hydrochloride 0.25% + midazolam 50 μg/kg in 2 ml saline 0.9%)
Study: 29446060
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (20 ml of bupivacaine hydrochloride 0.25% + 2 ml saline)
Study: 20170698
Drug: Non-Yokukansan (donepezil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-Yokukansan (donepezil monotherapy)
Study: 12472618
Drug: Lidocaine-prilocaine cream
Normalized name: lidocaine / prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine-prilocaine cream 5% applied for 20 min
Study: 12472618
Drug: Lidocaine-prilocaine cream
Normalized name: lidocaine / prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine-prilocaine cream 5% applied for 30 min
Study: 12472618
Drug: Lidocaine-prilocaine cream
Normalized name: lidocaine / prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine-prilocaine cream 5% applied for 45 min
Study: 12472618
Drug: Base cream
Normalized name: U-Base Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Base cream as placebo
Study: 18653121
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid treatment for 60 days
Study: 2573295
Drug: Adrenaline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline infusion after placebo pretreatment
Study: 2573295
Drug: Adrenaline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline infusion after atenolol pretreatment
Study: 2573295
Drug: Adrenaline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline infusion after propranolol pretreatment
Study: 2573295
Drug: Adrenaline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline infusion after beta-2-selective beta-blocking agent (ICI 118551)
Study: 29561428
Drug: ChondroT 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChondroT 1.0 g
Study: 29561428
Drug: ChondroT 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChondroT 2.0 g
Study: 12712245
Drug: 60 g
Normalized name: aspirin 60 Grains
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 g resistant starch (Novelose 260)
Study: 8658094
Drug: Furosemide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (1 mg/h)
Study: 24451130
Drug: Lycopene-enriched diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lycopene-enriched diet (20-25 mg/day of lycopene; through 30 g/day of triple concentrated tomato paste) for 6 months
Study: 12051113
Drug: Estradiol and
Normalized name: Estradiol and Norgestimate Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol and sequential levonorgestrel (50 micrograms/day estradiol for 2 weeks followed by 50 micrograms/day estradiol-10 micrograms/day levonorgestrel for 2 weeks)
Study: 12051113
Drug: Estradiol and
Normalized name: Estradiol and Norgestimate Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol and sequential levonorgestrel (75 micrograms/day estradiol for 2 weeks followed by 75 micrograms/day estradiol-15 micrograms/day levonorgestrel for 2 weeks)
Study: 12051113
Drug: Estradiol and
Normalized name: Estradiol and Norgestimate Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol and sequential levonorgestrel (100 micrograms/day estradiol for 2 weeks followed by 100 micrograms/day estradiol-20 micrograms/day levonorgestrel for 2 weeks)
Study: 12051113
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three doses of the transdermal hormone replacement therapy
Study: 8652176
Drug: Spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anesthesia with appropriate selection of drugs, techniques, and needles
Study: 26198890
Drug: Very early
Normalized name: Primula veris extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very early mobilisation (n=43) consisting of early and frequent out of bed activities starting within 24 hours of stroke onset for 5 to 30 minutes at least twice a day for seven days
Study: 18757184
Drug: Capsular polysaccharide-based
Normalized name: CAPSULAR POLYSACCHARIDE,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsular polysaccharide-based vaccine (StaphVAX)
Study: 18757184
Drug: Human immunoglobulin
Normalized name: Human immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human immunoglobulin G (IgG) preparation (INH-A21, Veronate)
Study: 10920157
Drug: Albuterol administered
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol administered through the spacer device (50 microg/kg)
Study: 10920157
Drug: Albuterol administered
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol administered through the nebulizer (150 microg/kg)
Study: 10920157
Drug: Albuterol administered
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol administered through the spacer device
Study: 10920157
Drug: Albuterol administered
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol administered through the nebulizer
Study: 8936492
Drug: Overnight glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overnight glucose infusion (5 mg.kg‐1.d‐1)
Study: 1543310
Drug: Intranasal cocaine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal cocaine, 2 mg/kg body weight
Study: 10866909
Drug: Multiple injections
Normalized name: sodium acetate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple injections
Study: 3904464
Drug: Conventional two-injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional two-injection treatment
Study: 31289017
Drug: Continuous intracoronary
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intracoronary adenosine (360 mcg/min)
Study: 31289017
Drug: Standard intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intravenous adenosine (140-180 mcg/kg/min)